Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate
This study is ongoing, but not recruiting participants.
Study NCT00510354
Information provided by Novartis
First Received: July 31, 2007
Last Updated: February 8, 2010
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
